期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
吉非替尼治疗晚期非小细胞肺癌的疗效观察 被引量:26
1
作者 宋霆婷 盖慧荣 +1 位作者 李伟 胡芳娟 《疑难病杂志》 CAS 2015年第8期778-781,共4页
目的分析吉非替尼和培美曲塞治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2011年1月—2013年12月收治的Ⅲb~Ⅳ期NSCLC患者共120例,按随机数字表法分为吉非替尼组和培美曲塞组各60例。吉非替尼组予以吉非替尼250 mg口服,每天1次,培... 目的分析吉非替尼和培美曲塞治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2011年1月—2013年12月收治的Ⅲb~Ⅳ期NSCLC患者共120例,按随机数字表法分为吉非替尼组和培美曲塞组各60例。吉非替尼组予以吉非替尼250 mg口服,每天1次,培美曲塞组予以500 mg/m^2静脉给药。2组患者治疗前后进行体力状况评分(PS)和国际生存质量肺癌治疗状态评价量表(FACT-L)评分。对比2组患者的近期疗效、治疗后生存情况和严重不良反应发生率。结果 2组患者治疗前后PS评分差异均无统计学意义(P>0.05)。与治疗前比较,2组患者治疗后的FACT-L评分中情感状况、躯体状况、社会/家庭情况、功能状况和肺癌特异模块均显著升高(P<0.05);且吉非替尼组上述指标均显著高于培美曲塞组(P<0.05)。吉非替尼组治疗后近期疗效显著优于培美曲塞组(31.66%vs.11.67%,χ~2=7.070,P<0.01)。吉非替尼组的中位治疗周期数、中位总生存期(OS)、6个月生存率、1年生存率、中位无进展生存期(PFS)和6个月PFS率显著高于培美曲塞组(P<0.05)。吉非替尼组治疗后的严重不良反应发生率为13.3%(3/60),显著低于培美曲塞组的31.7%(19/60),差异有统计学意义(χ~2=5.783,P<0.05)。结论吉非替尼治疗晚期NSCLC的临床疗效和生存率优于培美曲塞,同时不良反应发生率低,适合临床作为二线化疗方案应用。 展开更多
关键词 吉非替尼 培美曲塞 非小细胞肺癌 临床疗效
暂未订购
Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis 被引量:5
2
作者 Saul Levy-Blitchtein Stefany Plasencia-Rebata +1 位作者 Domingo Morales Luna Juana del Valle Mendoza 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第8期789-791,共3页
Papillary thyroid cancer(PTC)represents 80%-85%of thyroid cancer and its prevalence has been rising in the last decades.Primary thyroid lymphoma(PTL)accounts for 3%of extranodal lymphomas and about 5%of thyroid malign... Papillary thyroid cancer(PTC)represents 80%-85%of thyroid cancer and its prevalence has been rising in the last decades.Primary thyroid lymphoma(PTL)accounts for 3%of extranodal lymphomas and about 5%of thyroid malignancies,having a prevalence of one or two cases per million people.Mucosa-Associated Lymphoid Tissue lymphoma represents approximately30%of PTL.Both entities have an indolent course and a very good prognosis.Diagnosis is made by ultrasound and fine needle aspiration(FNA)or surgery specimen pathology.They have also been associated with Hashimoto’s thyroiditis(HT),but pathogenesis and its links remains to be known.Treatment remains controversial and surgery is generally accepted in cases of disease limited to thyroid,as the present.Patients with thyroid nodules should be observed and followed.If there is an enlargement by ultrasound or clinical symptoms,FNA should be performed promptly.Patients with HT deserve additional surveillance,since this condition is associated with both PTC and PTL.In this case,the management with surgery and radioactive iodine ablation therapy was effective for both entities.Patients with thyroid nodules should be properly evaluated with ultrasound and thyroid function tests.If there is an enlargement of the neck,reported by symptoms or ultrasound,it requires further investigation.HT is associated to both PTC and PTL so if the enlargement of the nodules is on this context additional tests such as FNA should be performed.In this case,the patient was managed with surgery and radioactive iodine ablation therapy and it was effective for both entities. 展开更多
关键词 THYROID cancer-clinical Hashimoto’s THYROIDITIS Pathology-thyroid THYROID DISEASES
暂未订购
Thyroid Nodule: Alpha Score 2.0 Classification for FNAB Selection, Multicentric Study in Latin America
3
作者 Glenn Mena Maria Cristina Chammas +14 位作者 Carlos Mario Gonzalez Vasquez Lylian Rocío Villagómez Marco Alfredo Muñoz Pico Patricio Alejandro Montalvo Santiago Mena-Bucheli Julio Olmedo Elizabeth Quintero Pedro Henrique de Marqui Moraes Osmar Cassio Saito Hubertino Diaz Denise Romero Gabriela Velalcazar Angel Ramón Sosa Fleitas Yamil Oliver Quevedo Ontaneda Victor Ricardo Chara 《Open Journal of Radiology》 2021年第4期160-174,共15页
<strong>Introduction:</strong> To perform a Latin-American multicentric study for the prediction of benign and malignant thyroid nodules using Alpha Score, and to compare it with ACR TIRADS<sup><s... <strong>Introduction:</strong> To perform a Latin-American multicentric study for the prediction of benign and malignant thyroid nodules using Alpha Score, and to compare it with ACR TIRADS<sup><span style="white-space:nowrap;">&#174;</span></sup> and Bethesda<sup><span style="white-space:nowrap;">&#174;</span></sup>. <strong>Materials and Methods:</strong> A prospective multicentric study in 10 radiological hospitals and institutions of Latin America was performed and 818 thyroid nodules were analyzed by ultrasound and classified by using both ACR TIRADS<sup><span style="white-space:nowrap;">&#174;</span></sup> and Alpha Score;fine-needle aspiration biopsy was performed when needed and classified with Bethesda. The relationships between predictors were analyzed by using binary logistic regression, statistical significance was defined by a p-value of 0.05, with an error margin of 4% and 95% confidence intervals. <strong>Results:</strong> Alpha Score 2.0 establishes five types of malignant predictors: microcalcifications, irregular borders, taller-than-wide shape, predominant solid texture and hypoechogenicity;a diameter equal to or greater than 1.5 cm adds an extra point to the final score. Resulting classification divides TNs into 4 categories: benign (1.9%), low suspicion (8.7%), mild suspicion (13.6%) and high suspicion (75.7%) of malignancy probability;sensitivity of 82%, specificity of 74%, the positive predictive value of 94%, the negative predictive value of 51%, the statistical accuracy of 81%, odds ratio of 108.89 and correlation with ACR TIRADS of 0.77 and Bethesda of 0.91.<strong> Conclusions: </strong>Alpha Score 2.0 has superior diagnostic accuracy and performance compared to the previously published Alpha Score and is able to classify a benign TN in a precise, safe and accurate way, avoiding unnecessary FNABs or determining the necessity of FNAB in cases of moderate to high suspicion of malignancy. 展开更多
关键词 Thyroid cancer-clinical Radiology-Imaging Thyroid Nodule Alpha Score TIRADS® Thyroid Ultrasonography
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部